The application for clinical application of the 3.1-class chemical drugs of HISCO, tolfatipu citrate and retamolin ointment, has been accepted

Tuofatipu citrate tablets (also known as tuofatipi citrate) belong to anti rheumatoid drugs Developed by Pfizer, it was listed in the United States for the first time on November 6, 2012, and listed companies such as China Stone Pharmaceutical Group and Kelun pharmaceutical have begun to lay out; another new drug, retamolin ointment, is a dermatologic drug In April 2007, GlaxoSmithKline FDA was approved for listing, and the patent expired in 2018 Huabang Yingtai (002004 SZ) also applied for the clinical application of the drug this year In the first half of the year, Hisense intensively applied for ten new drugs and made a first imitation In the first half of this year, hispec applied for 10 new drug preparations In addition to the two varieties mentioned above, there are also fondaparinux injection, enteral nutrition suspension (TP - Ⅱ), medium and long chain fat emulsion / amino acid (16) / glucose (16%) injection, dextran Lansoprazole for injection, dextran lansoprazole sustained-release capsule, ulinastate acetate, tenofovir dipivoxil fumarate tablets, ranolazine sustained-release tablets Tablets and other varieties, involving parenteral, enteral nutrition drugs, dermatology, rheumatoid, endocrine and other fields It is worth noting that these varieties are not produced by enterprises in China, and hisilico has become the "concentration camp" that impacts the first imitated varieties Hisico is the leader in the field of parenteral nutrition medicine, characteristic anti infection medicine and hepatobiliary disease medicine In the prospectus, the company has said that it will focus on tracking the development trend of innovative generic drugs in the international mainstream market, and establish the domestic leading new drug variety reserve resources.